No Non-Inferiority in Discontinuing Bevacizumab in Colorectal Cancer

Share this content:
No continuation of bevacizumab after first-line chemotherapy in metastatic colorectal cancer is not non-inferior to continuation.
No continuation of bevacizumab after first-line chemotherapy in metastatic colorectal cancer is not non-inferior to continuation.

No continuation of bevacizumab after first-line chemotherapy in patients with metastatic colorectal cancer is not non-inferior to continuation, according to a study published in Annals of Oncology.

Dieter Koeberle, MD, of the Kantonsspital St. Gallen and fellow researchers from Switzerland conducted an open-label, phase 3 multicenter trial where they looked at 262 patients with metastatic colorectal cancer.

After four to six months of standard first-line chemotherapy, patients were randomized to either continuation of bevacizumab at standard dosage or no treatment. Researchers performed CT scans every six weeks until disease progression.

RELATED: Genetic Variation Affects Colorectal Cancer Risk with Aspirin, NSAIDs

They found no non-inferiority in patients who did not continue with bevacizumab treatment. Median overall survival was 25.4 months in the continuation group versus 23.8 months in the no continuation group.

In addition, the cost for bevacizumab continuation was estimated at around $30,000 per patient.

“Based on no impact on overall survival and increased treatment costs, bevacizumab as a single agent is of no meaningful therapeutic value,” the authors concluded.

Reference

  1. Koeberle, D., et al. "Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)." Annals of Oncology. doi: 10.1093/annonc/mdv011. [epub ahead of print]. January 20, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters